Supporting Information

for

**Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease**

Shengnan Tang1,\*, Aiping Wang1,\*, Xiuju Yan1, Liuxiang Chu1, Xiucheng Yang1, Yina Song1, Kaoxiang Sun1 , Xin Yu1, Rongxia Liu1, Zimei Wu1, Peng Xue 2

1School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, Shandong Province, People’s Republic of China

2State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co., Ltd, Yantai, Shandong Province, People’s Republic of China

\*These authors contributed equally to this work.

Corresponding author:

Aiping Wang

School of Pharmacy, Yantai University, No 30 Qingquan road, Yantai, 264005, Shandong Province, People’s Republic of China

Tel: 86 535 39462458, Email: wangaiping@luye.com



**Figure S1**. Transmission Electron Microscopy (TEM) images of Lf-BNPs (Scare bar 100 nm).



**Figure S2**. Release profile of dopamine in PBS from free dopamine, dopamine-loaded NPs, Lf-NPs, and Lf-BNPs (n=3, mean ± SD).